Scholarlink

<p>Our study analyzes potential savings and losses for Medicare Part D using Mark Cuban Cost Plus Drug Company (MCCPDC) as an alternative medication procurement method for the 75 most commonly prescribed medications by otolaryngologists in 2022. Monthly standard MCCPDC costs and imputed Medicare Part D monthly costs for each prescription medication were compared. Our results indicated heterogenous efficiency of sourcing medications through MCCPDC due to some potential cost savings but other substantial losses. 45.3% of the top 75 otolaryngologic prescription medications sorted by total spending were not available on MCCPDC, indicating the need for more affordable access to expensive medications. Additionally, antibiotics consistently displayed potential losses through MCCPDC procurement, suggesting Medicare’s ability to achieve discount pricing for particular drug categories. Hence, providers should consider utilizing direct-to-consumer (DTC) models on a case-by-case basis, and future cost-saving investigations including additional DTC models should be conducted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Potential Cost Savings in Medicare Part D for Otolaryngologic Medications

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月28日

查看全文
  • Om B. Tripathi,
  • Aman M. Patel,
  • Hassaam S. Choudhry,
  • David W. Wassef,
  • Paul T. Cowan,
  • Richard Chan Woo Park,
  • Andrey Filimonov

摘要

Our study analyzes potential savings and losses for Medicare Part D using Mark Cuban Cost Plus Drug Company (MCCPDC) as an alternative medication procurement method for the 75 most commonly prescribed medications by otolaryngologists in 2022. Monthly standard MCCPDC costs and imputed Medicare Part D monthly costs for each prescription medication were compared. Our results indicated heterogenous efficiency of sourcing medications through MCCPDC due to some potential cost savings but other substantial losses. 45.3% of the top 75 otolaryngologic prescription medications sorted by total spending were not available on MCCPDC, indicating the need for more affordable access to expensive medications. Additionally, antibiotics consistently displayed potential losses through MCCPDC procurement, suggesting Medicare’s ability to achieve discount pricing for particular drug categories. Hence, providers should consider utilizing direct-to-consumer (DTC) models on a case-by-case basis, and future cost-saving investigations including additional DTC models should be conducted.